Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Beta Bionics Inc (NASDAQ: BBNX) was $15.2 for the day, down -3.86% from the previous closing price of $15.81. In other words, the price has decreased by -$3.86 from its previous closing price. On the day, 0.82 million shares were traded. BBNX stock price reached its highest trading level at $16.065 during the session, while it also had its lowest trading level at $14.75.
Ratios:
Our analysis of BBNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 13.79 and its Current Ratio is at 14.68. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $26.
On June 12, 2025, Lake Street started tracking the stock assigning a Buy rating and target price of $30.
On May 30, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $20.Wolfe Research initiated its Outperform rating on May 30, 2025, with a $20 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’25 when Sean Saint bought 3,439 shares for $17.89 per share.
Hopman Mark sold 868 shares of BBNX for $15,529 on Jun 02 ’25. The Chief Commercial Officer now owns 34,132 shares after completing the transaction at $17.89 per share. On Jun 02 ’25, another insider, Russell Steven Jon, who serves as the Chief Medical Officer of the company, sold 1,039 shares for $17.89 each. As a result, the insider received 18,588 and left with 72,032 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBNX now has a Market Capitalization of 660745536 and an Enterprise Value of 417712896. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.47 while its Price-to-Book (P/B) ratio in mrq is 2.19. Its current Enterprise Value per Revenue stands at 5.982 whereas that against EBITDA is -7.841.
Stock Price History:
Over the past 52 weeks, BBNX has reached a high of $24.50, while it has fallen to a 52-week low of $8.89. The 50-Day Moving Average of the stock is -3.71%, while the 200-Day Moving Average is calculated to be -2.79%.
Shares Statistics:
BBNX traded an average of 562.33K shares per day over the past three months and 853540 shares per day over the past ten days. A total of 43.47M shares are outstanding, with a floating share count of 33.31M. Insiders hold about 23.36% of the company’s shares, while institutions hold 83.41% stake in the company. Shares short for BBNX as of 1752537600 were 4802756 with a Short Ratio of 8.54, compared to 1749772800 on 4731224. Therefore, it implies a Short% of Shares Outstanding of 4802756 and a Short% of Float of 12.47.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Beta Bionics Inc (BBNX) is currently being evaluated by a team of 5 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.4, with high estimates of -$0.34 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$1.76 and -$2.24 for the fiscal current year, implying an average EPS of -$2.03. EPS for the following year is -$1.85, with 5.0 analysts recommending between -$1.52 and -$2.03.
Revenue Estimates
For the next quarter, 8 analysts are estimating revenue of $26.4M. There is a high estimate of $27.65M for the next quarter, whereas the lowest estimate is $24.3M.
A total of 8 analysts have provided revenue estimates for BBNX’s current fiscal year. The highest revenue estimate was $92.86M, while the lowest revenue estimate was $88.8M, resulting in an average revenue estimate of $91.19M. In the same quarter a year ago, actual revenue was $65.12MBased on 8 analysts’ estimates, the company’s revenue will be $122.03M in the next fiscal year. The high estimate is $132.79M and the low estimate is $113.1M.
